NAMS Menopause Certification Elite Board Review
Updated 2026 | Practice Questions & Verified
Answers | Ultimate Menopause Society
Certification Exam Prep, Comprehensive Women's
Health Study Guide, Hormone Therapy (HT),
Perimenopause, Postmenopause, Vasomotor
Symptoms, Genitourinary Syndrome of Menopause
(GSM), Bone Health, Cardiovascular Risk, Sexual
Medicine, Evidence-Based Clinical Practice,
Detailed Rationales
Question 1: A 52-year-old woman reports that her once-predictable menstrual
cycles have become irregular over the last 8 months, with flow varying from
scanty to heavy. She has also experienced hot flushes and night sweats. Which
stage of the STRAW+10 staging system best describes her current status?
A. Early reproductive stage
B. Late reproductive stage
C. Early menopausal transition
D. Late menopausal transition
CORRECT ANSWER: C. Early menopausal transition
Rationale: The STRAW+10 criteria define the early menopausal transition as beginning
with a persistent change in cycle length of 7 days or more, accompanied by variations in
flow and the onset of vasomotor symptoms. This stage typically occurs in the late 40s to
early 50s and is characterized by elevated FSH levels.
Question 2: Which hormonal change is most characteristic of the early
perimenopausal transition?
A. Decreased levels of follicle-stimulating hormone (FSH)
B. Increased levels of anti-Müllerian hormone (AMH)
C. Elevated and highly variable follicle-stimulating hormone (FSH) levels
D. Suppressed luteinizing hormone (LH) levels
CORRECT ANSWER: C. Elevated and highly variable follicle-stimulating
hormone (FSH) levels
Rationale: As ovarian reserve declines, the pituitary gland increases FSH secretion in
an attempt to stimulate the remaining follicles. This results in elevated and highly
variable FSH levels, particularly during the early follicular phase, a hallmark of the
menopausal transition.
,Question 3: A 49-year-old patient with a history of hypertension and migraines
with aura is seeking relief from severe vasomotor symptoms. Which of the
following is the MOST appropriate first-line pharmacological intervention?
A. Conjugated equine estrogens plus medroxyprogesterone acetate
B. Transdermal estradiol patch
C. Oral ethinyl estradiol combination contraceptive
D. Tibolone
CORRECT ANSWER: B. Transdermal estradiol patch
Rationale: For a patient with hypertension and migraines with aura, transdermal
estradiol is preferred because it avoids the first-pass hepatic effect, reducing the risk of
venous thromboembolism and blood pressure elevation. The oral route and ethinyl
estradiol are contraindicated in this context due to increased cardiovascular and stroke
risk.
Question 4: What is the primary mechanism by which selective serotonin
reuptake inhibitors (SSRIs) improve vasomotor symptoms in menopausal
women?
A. Peripheral vasodilation through nitric oxide release
B. Central modulation of the thermoregulatory center in the hypothalamus
C. Direct stimulation of estrogen receptors in the brainstem
D. Inhibition of prostaglandin synthesis in the preoptic area
CORRECT ANSWER: B. Central modulation of the thermoregulatory center in
the hypothalamus
Rationale: SSRIs act centrally by modulating neurotransmitters like serotonin and
norepinephrine in the hypothalamic thermoregulatory center, which helps stabilize the
core body temperature set point and reduce the frequency and severity of hot flushes.
Question 5: Which of the following is a known risk factor for the development
of genitourinary syndrome of menopause (GSM)?
A. Parity of more than three children
B. High body mass index (BMI)
C. Long-term use of combined oral contraceptives
D. Cigarette smoking
CORRECT ANSWER: D. Cigarette smoking
Rationale: Cigarette smoking is associated with an earlier onset of menopause and
increased risk of urogenital atrophy due to its anti-estrogenic effects and negative
impact on vaginal tissue vascularity and health.
,Question 6: A 55-year-old woman is on hormone therapy with an estradiol
patch and oral micronized progesterone. She is concerned about breast cancer
risk. Which statement accurately reflects the breast cancer risk associated
with this regimen?
A. Estrogen-alone therapy increases breast cancer risk more than combined therapy.
B. Combined continuous therapy is associated with a higher risk than estrogen alone.
C. Micronized progesterone has a higher risk profile than synthetic progestins.
D. There is no difference in risk between transdermal and oral estrogen.
CORRECT ANSWER: B. Combined continuous therapy is associated with a
higher risk than estrogen alone.
Rationale: Large epidemiologic studies, including the WHI, have shown that combined
estrogen-progestin therapy is associated with a higher relative risk of breast cancer than
estrogen-alone therapy, especially with continuous combined regimens.
Question 7: Which of the following bone turnover markers is MOST useful for
monitoring the early response to antiresorptive therapy in postmenopausal
osteoporosis?
A. Serum calcium
B. Urinary N-telopeptide (NTx)
C. Serum alkaline phosphatase
D. 25-hydroxyvitamin D
CORRECT ANSWER: B. Urinary N-telopeptide (NTx)
Rationale: Urinary N-telopeptide (NTx) is a specific marker of bone resorption. It
responds rapidly to antiresorptive therapy, with significant decreases observed within 3
to 6 months, making it valuable for monitoring treatment efficacy.
Question 8: A 48-year-old woman presents with a chief complaint of vaginal
dryness and dyspareunia. She is not interested in systemic hormone therapy.
Which of the following is the MOST appropriate localized treatment?
A. Oral ospemifene daily
B. Vaginal estradiol tablets (10 mcg)
C. Systemic transdermal estradiol patch
D. Prasterone (DHEA) vaginal insert
CORRECT ANSWER: D. Prasterone (DHEA) vaginal insert
Rationale: Prasterone (DHEA) is FDA-approved for moderate-to-severe dyspareunia. It
acts locally as a tissue-regenerative agent and is suitable for patients who prefer a non-
, estrogen or local alternative, although the correct term for "local estrogen" must be
carefully selected. For this question, Prasterone is preferred because it is not systemic,
unlike the other options which either are systemic or have systemic absorption effects.
Question 9: Which of the following is considered a contraindication to the use
of menopausal hormone therapy?
A. History of superficial venous thrombosis
B. Migraines without aura
C. Personal history of breast cancer
D. Hypothyroidism
CORRECT ANSWER: C. Personal history of breast cancer
Rationale: A personal history of breast cancer is an absolute contraindication to
systemic hormone therapy due to the estrogen-dependent nature of many breast tumors
and the risk of disease recurrence.
Question 10: A 56-year-old patient taking alendronate for osteoporosis reports
new-onset heartburn and esophageal irritation. What is the MOST appropriate
next step in management?
A. Switch to an intravenous bisphosphonate.
B. Increase the dose of alendronate.
C. Add a proton pump inhibitor.
D. Discontinue the medication permanently.
CORRECT ANSWER: A. Switch to an intravenous bisphosphonate.
Rationale: Alendronate-induced esophageal irritation is often related to oral
administration. Switching to an intravenous bisphosphonate, such as zoledronic acid,
bypasses the gastrointestinal tract, reducing the risk of esophagitis while maintaining
efficacy.
Question 11: In the context of hormone therapy, which progestogen is LEAST
likely to negate the beneficial effects of estrogen on lipid profiles?
A. Medroxyprogesterone acetate
B. Norethindrone acetate
C. Levonorgestrel
D. Micronized progesterone
CORRECT ANSWER: D. Micronized progesterone
Updated 2026 | Practice Questions & Verified
Answers | Ultimate Menopause Society
Certification Exam Prep, Comprehensive Women's
Health Study Guide, Hormone Therapy (HT),
Perimenopause, Postmenopause, Vasomotor
Symptoms, Genitourinary Syndrome of Menopause
(GSM), Bone Health, Cardiovascular Risk, Sexual
Medicine, Evidence-Based Clinical Practice,
Detailed Rationales
Question 1: A 52-year-old woman reports that her once-predictable menstrual
cycles have become irregular over the last 8 months, with flow varying from
scanty to heavy. She has also experienced hot flushes and night sweats. Which
stage of the STRAW+10 staging system best describes her current status?
A. Early reproductive stage
B. Late reproductive stage
C. Early menopausal transition
D. Late menopausal transition
CORRECT ANSWER: C. Early menopausal transition
Rationale: The STRAW+10 criteria define the early menopausal transition as beginning
with a persistent change in cycle length of 7 days or more, accompanied by variations in
flow and the onset of vasomotor symptoms. This stage typically occurs in the late 40s to
early 50s and is characterized by elevated FSH levels.
Question 2: Which hormonal change is most characteristic of the early
perimenopausal transition?
A. Decreased levels of follicle-stimulating hormone (FSH)
B. Increased levels of anti-Müllerian hormone (AMH)
C. Elevated and highly variable follicle-stimulating hormone (FSH) levels
D. Suppressed luteinizing hormone (LH) levels
CORRECT ANSWER: C. Elevated and highly variable follicle-stimulating
hormone (FSH) levels
Rationale: As ovarian reserve declines, the pituitary gland increases FSH secretion in
an attempt to stimulate the remaining follicles. This results in elevated and highly
variable FSH levels, particularly during the early follicular phase, a hallmark of the
menopausal transition.
,Question 3: A 49-year-old patient with a history of hypertension and migraines
with aura is seeking relief from severe vasomotor symptoms. Which of the
following is the MOST appropriate first-line pharmacological intervention?
A. Conjugated equine estrogens plus medroxyprogesterone acetate
B. Transdermal estradiol patch
C. Oral ethinyl estradiol combination contraceptive
D. Tibolone
CORRECT ANSWER: B. Transdermal estradiol patch
Rationale: For a patient with hypertension and migraines with aura, transdermal
estradiol is preferred because it avoids the first-pass hepatic effect, reducing the risk of
venous thromboembolism and blood pressure elevation. The oral route and ethinyl
estradiol are contraindicated in this context due to increased cardiovascular and stroke
risk.
Question 4: What is the primary mechanism by which selective serotonin
reuptake inhibitors (SSRIs) improve vasomotor symptoms in menopausal
women?
A. Peripheral vasodilation through nitric oxide release
B. Central modulation of the thermoregulatory center in the hypothalamus
C. Direct stimulation of estrogen receptors in the brainstem
D. Inhibition of prostaglandin synthesis in the preoptic area
CORRECT ANSWER: B. Central modulation of the thermoregulatory center in
the hypothalamus
Rationale: SSRIs act centrally by modulating neurotransmitters like serotonin and
norepinephrine in the hypothalamic thermoregulatory center, which helps stabilize the
core body temperature set point and reduce the frequency and severity of hot flushes.
Question 5: Which of the following is a known risk factor for the development
of genitourinary syndrome of menopause (GSM)?
A. Parity of more than three children
B. High body mass index (BMI)
C. Long-term use of combined oral contraceptives
D. Cigarette smoking
CORRECT ANSWER: D. Cigarette smoking
Rationale: Cigarette smoking is associated with an earlier onset of menopause and
increased risk of urogenital atrophy due to its anti-estrogenic effects and negative
impact on vaginal tissue vascularity and health.
,Question 6: A 55-year-old woman is on hormone therapy with an estradiol
patch and oral micronized progesterone. She is concerned about breast cancer
risk. Which statement accurately reflects the breast cancer risk associated
with this regimen?
A. Estrogen-alone therapy increases breast cancer risk more than combined therapy.
B. Combined continuous therapy is associated with a higher risk than estrogen alone.
C. Micronized progesterone has a higher risk profile than synthetic progestins.
D. There is no difference in risk between transdermal and oral estrogen.
CORRECT ANSWER: B. Combined continuous therapy is associated with a
higher risk than estrogen alone.
Rationale: Large epidemiologic studies, including the WHI, have shown that combined
estrogen-progestin therapy is associated with a higher relative risk of breast cancer than
estrogen-alone therapy, especially with continuous combined regimens.
Question 7: Which of the following bone turnover markers is MOST useful for
monitoring the early response to antiresorptive therapy in postmenopausal
osteoporosis?
A. Serum calcium
B. Urinary N-telopeptide (NTx)
C. Serum alkaline phosphatase
D. 25-hydroxyvitamin D
CORRECT ANSWER: B. Urinary N-telopeptide (NTx)
Rationale: Urinary N-telopeptide (NTx) is a specific marker of bone resorption. It
responds rapidly to antiresorptive therapy, with significant decreases observed within 3
to 6 months, making it valuable for monitoring treatment efficacy.
Question 8: A 48-year-old woman presents with a chief complaint of vaginal
dryness and dyspareunia. She is not interested in systemic hormone therapy.
Which of the following is the MOST appropriate localized treatment?
A. Oral ospemifene daily
B. Vaginal estradiol tablets (10 mcg)
C. Systemic transdermal estradiol patch
D. Prasterone (DHEA) vaginal insert
CORRECT ANSWER: D. Prasterone (DHEA) vaginal insert
Rationale: Prasterone (DHEA) is FDA-approved for moderate-to-severe dyspareunia. It
acts locally as a tissue-regenerative agent and is suitable for patients who prefer a non-
, estrogen or local alternative, although the correct term for "local estrogen" must be
carefully selected. For this question, Prasterone is preferred because it is not systemic,
unlike the other options which either are systemic or have systemic absorption effects.
Question 9: Which of the following is considered a contraindication to the use
of menopausal hormone therapy?
A. History of superficial venous thrombosis
B. Migraines without aura
C. Personal history of breast cancer
D. Hypothyroidism
CORRECT ANSWER: C. Personal history of breast cancer
Rationale: A personal history of breast cancer is an absolute contraindication to
systemic hormone therapy due to the estrogen-dependent nature of many breast tumors
and the risk of disease recurrence.
Question 10: A 56-year-old patient taking alendronate for osteoporosis reports
new-onset heartburn and esophageal irritation. What is the MOST appropriate
next step in management?
A. Switch to an intravenous bisphosphonate.
B. Increase the dose of alendronate.
C. Add a proton pump inhibitor.
D. Discontinue the medication permanently.
CORRECT ANSWER: A. Switch to an intravenous bisphosphonate.
Rationale: Alendronate-induced esophageal irritation is often related to oral
administration. Switching to an intravenous bisphosphonate, such as zoledronic acid,
bypasses the gastrointestinal tract, reducing the risk of esophagitis while maintaining
efficacy.
Question 11: In the context of hormone therapy, which progestogen is LEAST
likely to negate the beneficial effects of estrogen on lipid profiles?
A. Medroxyprogesterone acetate
B. Norethindrone acetate
C. Levonorgestrel
D. Micronized progesterone
CORRECT ANSWER: D. Micronized progesterone
